Sellas Life Sciences Group (ehemals Galena Biopharma) (Seite 147)
eröffnet am 30.10.12 22:43:19 von
neuester Beitrag 05.05.24 17:10:19 von
neuester Beitrag 05.05.24 17:10:19 von
Beiträge: 2.941
ID: 1.177.530
ID: 1.177.530
Aufrufe heute: 2
Gesamt: 345.900
Gesamt: 345.900
Aktive User: 0
ISIN: US81642T2096 · WKN: A2PU3T · Symbol: SLS
1,2900
USD
+0,78 %
+0,0100 USD
Letzter Kurs 02:00:00 Nasdaq
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8550 | +147,33 | |
| 0,5700 | +55,23 | |
| 5,4500 | +41,56 | |
| 150,47 | +38,68 | |
| 1,0000 | +33,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,2500 | -19,23 | |
| 0,7300 | -19,34 | |
| 18,280 | -21,55 | |
| 2,1400 | -24,11 | |
| 1,5100 | -24,12 |
Beitrag zu dieser Diskussion schreiben
Feedback
Hoffe sehr das GALE ein wesentliche Beitrag hiebei leisten wird....
http://www.breastcancerdeadline2020.org/about-the-deadline/
http://www.breastcancerdeadline2020.org/about-the-deadline/
Quickly closing in an E75's Endspurt....
...und 'falls' dieses vom Erfolg gekrönt wird, folgen die weiteren "Indikationen" im verlinkte Testbereiche (siehe Chart) fast vom selbst.
Bin ja gespannt wie der Markt-mit etwas vertiefte schutzenhilfe durch Beth Mittendorff- dann wohl reagieren mag?!?
...und 'falls' dieses vom Erfolg gekrönt wird, folgen die weiteren "Indikationen" im verlinkte Testbereiche (siehe Chart) fast vom selbst.
Bin ja gespannt wie der Markt-mit etwas vertiefte schutzenhilfe durch Beth Mittendorff- dann wohl reagieren mag?!?
From Rocketjock & Cyntiques100 over at Yahoo, Lesenswert -(der dortige thread Any updates on this morning's presentation ?- meiner Meinung nach ....
Well, my model estimates the 70th event would occur on September 11th (This Friday) if Neuvax recurrence reduction is 30% from the CA (CA @22.2% recurrence). I have pondered how long it might take from time of the 70th event to notification of shareholders and haven't found anything concrete on which to base an estimate. We know that it took two months for the company to let us know that the Cardiac Toxicity monitoring had been reduced by the IDMC. Being that the 70th event is a much more material event than cardiac toxicity, my hope is the information will be disseminated with days of it becoming known. Maybe, 7 days for attending physician to verify cancer recurrence plus 1 day for data transmittal to IDMC plus 5 days for data compilation/assessment and report issuance plus 2 days for Galena to approve and make a news release for a total of 15 days from model recurrence date.
Yes, I thought Schwartz did an excellent job, considering he only had less than 25 minutes. He covered a lot of ground. Visual presentation was comprehensive, yet concise and focused to hit on critical investor interests. IMO, the key take out from this presentation was his verbal confirmation that there "will be" additional data from GALE-301 P1/2a trial presented at ESMO later this month.
http://finance.yahoo.com/mbview/threadview/;_ylt=Ai2JW6q3hgX…
...eins ist jedenfalls klar, wir sind erheblich näher dran als je zuvor in GALE's historie- this is (shoulld be) our season!
Well, my model estimates the 70th event would occur on September 11th (This Friday) if Neuvax recurrence reduction is 30% from the CA (CA @22.2% recurrence). I have pondered how long it might take from time of the 70th event to notification of shareholders and haven't found anything concrete on which to base an estimate. We know that it took two months for the company to let us know that the Cardiac Toxicity monitoring had been reduced by the IDMC. Being that the 70th event is a much more material event than cardiac toxicity, my hope is the information will be disseminated with days of it becoming known. Maybe, 7 days for attending physician to verify cancer recurrence plus 1 day for data transmittal to IDMC plus 5 days for data compilation/assessment and report issuance plus 2 days for Galena to approve and make a news release for a total of 15 days from model recurrence date.
Yes, I thought Schwartz did an excellent job, considering he only had less than 25 minutes. He covered a lot of ground. Visual presentation was comprehensive, yet concise and focused to hit on critical investor interests. IMO, the key take out from this presentation was his verbal confirmation that there "will be" additional data from GALE-301 P1/2a trial presented at ESMO later this month.
http://finance.yahoo.com/mbview/threadview/;_ylt=Ai2JW6q3hgX…
...eins ist jedenfalls klar, wir sind erheblich näher dran als je zuvor in GALE's historie- this is (shoulld be) our season!
Antwort auf Beitrag Nr.: 50.601.227 von alfarr27 am 11.09.15 05:34:49Wie jetzt "nur" 3$ ?!?...der ist entweder Schotte, oder Witzbold (aber zweimal überlegt, evtl. sogar beides 
)
)
Antwort auf Beitrag Nr.: 50.594.054 von Growth2012 am 10.09.15 09:41:37Und noch eins...
Galena Biopharma Now Covered by Analysts at Raymond James (GALE)
Raymond James assumed coverage on shares of Galena Biopharma (NASDAQ:GALE) in a research note issued to investors on Wednesday morning, The Fly reports. The firm issued an outperform rating and a $3.00 price objective on the biotechnology company’s stock.
http://sleekmoney.com/galena-biopharma-now-covered-by-analys…
Galena Biopharma Now Covered by Analysts at Raymond James (GALE)
Raymond James assumed coverage on shares of Galena Biopharma (NASDAQ:GALE) in a research note issued to investors on Wednesday morning, The Fly reports. The firm issued an outperform rating and a $3.00 price objective on the biotechnology company’s stock.
http://sleekmoney.com/galena-biopharma-now-covered-by-analys…
Trading Spotlight
Moin, moin, zwar vom ende August, aber war dieses schon bekannt?
Analysts Set Galena Biopharma Target Price at >>>$5.17<<< (NASDAQ:GALE)
http://sleekmoney.com/analysts-set-galena-biopharma-target-p…
Analysts Set Galena Biopharma Target Price at >>>$5.17<<< (NASDAQ:GALE)
http://sleekmoney.com/analysts-set-galena-biopharma-target-p…
nachbörslich kleiner Umsatz! Vielleicht weis da schon jemand mehr auf der healthcare investment conferences?
wann kommt hier der Turbo????
Durchsuchen
